Case Study of the Access to the Bacillus Calmette-Guérin Vaccine Against Tuberculosis in the United States

Dec 2009

Bacillus Calmette-Guérin (BCG) is a vaccine that is used worldwide to prevent tuberculosis. Some developed countries, such as the United States, do not routinely administer this vaccine. This article presents the case study of a family who struggled to obtain the BCG in the months before a planned trip to a country in which tuberculosis is prevalent. The application of the BCG vaccination and its availability in the United States, particularly for children, is discussed.

Article PDF cannot be displayed. You can download it here:

https://nsuworks.nova.edu/cgi/viewcontent.cgi?article=1224&context=ijahsp

Case Study of the Access to the Bacillus Calmette-Guérin Vaccine Against Tuberculosis in the United States

A Peer Reviewed Publication of the College of Allied Health & Nursing at Nova Southeastern University Dedicated to allied health professional practice and education http://ijahsp.nova.edu Vol. 7 No. 1 ISSN 1540-580X Case Study of the Access to the Bacillus Calmette-Guérin Vaccine against Tuberculosis in the United States Dewan Raja, MBBS Palmer College of Chiropractic, Florida United States CITATION: Raja, D. Case Study of the Access to the Bacillus Calmette-Guérin Vaccine against Tuberculosis in the United States. The Internet Journal of Allied Health Sciences and Practice. Jan 2009, Volume 7 Number 1. ABSTRACT Bacillus Calmette-Guérin (BCG) is a vaccine that is used worldwide to prevent tuberculosis. Some developed countries, such as the United States, do not routinely administer this vaccine. This article presents the case study of a family who struggled to obtain the BCG in the months before a planned trip to a country in which tuberculosis is prevalent. The application of the BCG vaccination and its availability in the United States, particularly for children, is discussed. CASE REPORT (2008) A couple residing in Port Orange, Florida, USA, planned to take their young child to visit Bangladesh, where tuberculosis is prevalent. The parents believed that the Bacillus Calmette-Guérin (BCG) vaccine would be routinely administered to their child because it is commonly provided to all newborns in many parts of the world. At the age of 22 months, she had not received a BCG vaccination, despite the efforts of her parents to try to obtain one for her. Concerned that the child would be exposed to tuberculosis during the family’s month-long trip, they asked their family practice physician for a BCG vaccination during well-child visits and at other immunizations. The physician was hesitant, because the BCG vaccine is not generally given to children in the United States, but requested a BCG vaccine from the Centers for Disease Control and Prevention. The vaccine was obtained after 8 months. The tuberculin syringe specific for BCG vaccination was not available at the well-child clinic, and the child was inoculated by a nurse with no experience in administering the BCG vaccine. The BCG vaccine is typically administered in a highly specific manner, intradermally over the deltoid muscle, by a trained specialist. In this family’s case, the vaccine was administered via multiple punctures of the skin on the anterolateral aspect of the left thigh. There was no immediate or delayed skin reaction at the vaccination site. The physician advised that a tuberculin sensitivity test (Mantoux test) be performed on the child after 2 to 3 months to confirm reactivity. No reaction was observed with the tuberculin sensitivity test. The physician advised a repeat BCG vaccination. The child’s parents consulted a pediatrician at a different facility who thought he could more easily obtain the BCG vaccine. However, this was not the case, and the pediatrician advised the parents to get the child inoculated in the country of travel,. The initial physician, at the family practice office, also found himself unable to obtain the vaccine; he stated that it would take several months to get additional vaccine. In response to their inability to obtain a second vaccine, the family decided to postpone their trip for 6 months. © The Internet Journal of Allied Health Sciences and Practice, 2009 Case Study of the Access to the Bacillus Calmette-Guérin Vaccine against Tuberculosis in the United States 2 OVERVIEW Tuberculosis is an infectious disease caused by the bacterium Mycobacterium tuberculosis. Infection via contaminated droplets is the typical mode of transmission. It also may be transmitted in unpasteurized milk. Tuberculosis is prevalent in third-world countries, where overcrowding and poor sanitation are common. Bacillus Calmette-Guérin is a vaccine for preventing tuberculosis. It is provided to newborns in more than 100 countries with a high prevalence of tuberculosis to prevent childhood tuberculosis, tubercular meningitis, and miliary tuberculosis.1 According to the Center for Disease Control Website, “Bacillus Calmette-Guérin vaccination is not generally administered in the United States because of the low prevalence of tuberculosis, the variable effectiveness of the vaccine against adult pulmonary tuberculosis, and the vaccine’s potential interference with the tuberculin sensitivity test. Bacillus Calmette-Guérin vaccination is advised only for specific individuals who meet certain criteria that places them at greater risk for infection, and on the recommendation of a tuberculosis specialist.”2 EPIDEMIOLOGY Infection by the M. tuberculosis bacterium is estimated to result in 8.3 million new cases of tuberculosis and approximately 2 million deaths worldwide annually, making it the second leading cause of death from infectious disease in the world.3 From 1985 to 1994, the number of tuberculosis cases in the United States among children youger than 15 years of age increased 33%, from 1257 to 1675 cases, and the total number of cases increased 18%, from 2.42 to 2.85 per 100,000 in the population.4 More than 14,000 cases were reported in the United States in 2005. The increasing number of children with tuberculosis in the United States suggests the continuing spread of M. tuberculosis within American communities, and indicates a need for assertive monitoring of children in contact with infected adults. The large increase in cases among minorities and foreign-born individuals emphasizes the need to target prevention and control activities to these groups.5 The Centers for Disease Control and Prevention recommends that the BCG vaccination should be administered only to children who have a negative tuberculin sensitivity test and are persistently exposed to, and cannot be isolated from, adults who are untreated or unsuccessfully treated for tuberculosis, or who have tuberculosis caused by drug-resistant strains of M. tuberculosis.6 DISCUSSION It is difficult to identify individuals who are untreated or ineffectively treated for tuberculosis, particularly in third-world countries. Many individuals do not know they are infected and may consequently go on to infect others. Many who do know they are infected feel stigmatized and hide the fact that they have the disease. Tuberculosis can be contracted during airplane trips as well as at supermarkets, hotels, and other places where people congregate. A significant number of people infected with TB are identified during chest radiographs, prescribed for reasons unrelated to TB. The current World Health Organization recommendation for treatment of TB is a 6-month regimen of multiple oral medications. However, many infected individuals do not take their medications, in part, perhaps, because it can be prohibitively expensive, yet, many patients are unaware that government subsidies of tuberculosis medications exist. On average, BCG vaccine decreases the risk of (...truncated)


This is a preview of a remote PDF: https://nsuworks.nova.edu/cgi/viewcontent.cgi?article=1224&context=ijahsp
Article home page: https://nsuworks.nova.edu/ijahsp/vol7/iss1/5

Dewan Raja. Case Study of the Access to the Bacillus Calmette-Guérin Vaccine Against Tuberculosis in the United States, 2009, pp. 5, Volume 7, Issue 1,